ClinicalTrials.gg
RecruitingNCT07871435Updated Nov 9, 2026

GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)

A Phase 1/2 interventional study of GI-102 and Pasritamig in Metastatic Castration-resistant Prostate Cancer (mCRPC), sponsored by GI Innovation, Inc.. Recruiting at 6 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by GI Innovation, Inc. · Phase 1/2, Interventional, and Treatment

Updated Nov 9, 2026Site recruiting status changedInterventions changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
107
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 198 studies in Prostatic Neoplasms with a site in Korea, Republic of — 48 open to participants now, 81 under way, 37 of them phase 3. Prostatic Neoplasms · Korea, Republic of.

Planned enrollment
109th of 165
107 · median 208
Started
2026
with 15 others
Phase 1/2
15 of 198
9 open now
Primary completion
2029-03
later than 62 of 80 live
Registered
198th of 198
by date

Among the 198 studies in Prostatic Neoplasms with a site in Korea, Republic of, this one is the 109th largest by planned enrollment of the 165 interventional ones that give a count, is one of 16 that started in 2026, is one of 15 in phase 1/2, reaches primary completion later than 62 of the 80 other live ones, and was the 198th registered.

Prostatic Neoplasms

7,053 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

48 of the 198 studies in Prostatic Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:

42 more — sign in →

All 48 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Prostatic Neoplasms with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to evaluate the safety, tolerability, and preliminary anti-cancer activity of GI-102 in combination with pasritamig in adult men with metastatic castration-resistant prostate cancer (mCRPC) whose cancer has progressed after previous treatment with a novel hormonal therapy (NHT).

03

Conditions studied

  • Metastatic Castration-resistant Prostate Cancer (mCRPC)

Browse trials for

Keywords

  • Metastatic castration-resistant prostate cancer
  • Immunotherapy
  • GI-102
  • CD80-IgG4 Fc-IL2 variant
  • Interleukin-2
  • Immunocytokine
  • bispecific protein
  • pasritamig
  • T cell engager
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male participants aged ≥18 years (or ≥19 years according to local regulatory requirements).
  • performance status of 0 to 1.
  • confirmed advanced prostate adenocarcinoma with measurable or evaluable disease. Adenocarcinoma with small cell or neuroendocrine (NE) features is permitted. However, primary small cell carcinoma, carcinoid tumor, mixed NE carcinoma, or large cell NE carcinoma (or pathologic evidence of conversion to) is disallowed.
  • castration-resistant prostate cancer (mCRPC) with documented disease progression following at least one line of novel androgen receptor-targeted therapy.
  • PSA ≥2 ng/mL at screening.
  • No more than 2 prior taxane regimens and no prior cytotoxic chemotherapy other than taxane therapy.
  • Prior orchiectomy or ongoing androgen deprivation therapy with castrate testosterone levels.
  • Adequate organ and marrow function and adequate cardiovascular function.
  • Adequate recovery from prior anticancer therapy-related adverse events.
  • Willingness and ability to comply with study procedures and protocol-specified requirements.

Key Exclusion Criteria:

  • Active or prior , carcinomatous meningitis, or clinically unstable spinal cord compression.
  • Significant uncontrolled cardiovascular, pulmonary, hepatic, , infectious, or other systemic disease.
  • Active or recent infection, including active tuberculosis, , or .
  • Active pneumonitis or interstitial lung disease (ILD), or history of clinically significant pneumonitis/ILD.
  • Recent treatment with products, prohibited immunomodulating agents, radiotherapy, major surgery, or other protocol-defined prohibited therapies.
  • Prior treatment with CD3-directed therapies, including KLK2-CD3 bispecific antibodies or other CD3-targeting T-cell engagers.
  • Known to GI-102, pasritamig, or their , or any other condition that may interfere with study participation or interpretation of results.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
107 participants (estimated)

Study arms

  • Experimental
    Safety run-in: GI-102 + pasritamig (Schedule A)

    Participants receive GI-102 in combination with pasritamig during the Safety run-in phase. Dose escalation is guided by a Bayesian Optimal Interval (BOIN) design.

    Drug: GI-102 · Drug: Pasritamig

  • Experimental
    Safety run-in: GI-102 + pasritamig (Schedule B)

    Participants receive GI-102 in combination with pasritamig during the Safety run-in phase. Dose escalation is guided by a Bayesian Optimal Interval (BOIN) design.

    Drug: GI-102 · Drug: Pasritamig

  • Experimental
    Expansion

    Participants enrolled in the Expansion phase will receive the combination recommended Phase 2 regimen (cRP2R) of GI-102 and pasritamig, determined based on the safety and dose-escalation results from the Safety run-in phase.

    Drug: GI-102 · Drug: Pasritamig

Interventions

  • DrugGI-102

    GI-102 will be administered in accordance with the procedures specified in the study protocol.

  • Pasritamig will be administered in accordance with the procedures specified in the study protocol.

06

What researchers measure

Primary outcomes

  1. Incidence and nature of DLTs (Safety run-in phase)

    A DLT is defined as a clinically significant AE (classified according to the NCI CTCAE version 6.0) or significant laboratory abnormality that occur during the DLT assessment periods, and is considered by the Investigator to be related to the study drug(s).

    Time frame: From Day -14 to Cycle 1 Day 22 (35 days)

  2. Incidence, nature, and severity of AEs graded according to CTCAE v6.0 (Safety run-in phase)

    An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. All AE events will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 6.0.

    Time frame: Up to 2 years

  3. PSA response rate (≥ 50% decline from baseline) per PCWG3 (Expansion phase)

    PSA response rate is defined as the percentage of participants with a decline of PSA of 50% or more from baseline.

    Time frame: Up to 2 years

Secondary outcomes

  1. PSA response rate (≥ 50% and ≥ 90% decline from baseline) per PCWG3 (Safety run-in phase)

    PSA response rate is defined as the percentage of participants with a decline of PSA of 50% (or 90%) or more from baseline.

    Time frame: Up to 2 years

  2. Radiographic PFS per PCWG3

    Radiographic PFS is defined as the time from the date of first dose of any study treatment until the date of radiographic disease progression or death, whichever comes first.

    Time frame: Up to 2 years

  3. Time to PSA progression

    Time to PSA progression, defined as the time from baseline to the first date of documented PSA progression per PCWG3 criteria.

    Time frame: Up to 2 years

  4. Overall Response Rate (ORR) per RECIST v1.1

    Among participants with measurable disease, ORR is defined as the percentage of participants who achieve a partial response (PR) or complete response (CR) according to RECIST v1.1.

    Time frame: Up to 2 years

  5. Duration of Response (DoR) per RECIST v1.1

    Among participants with measurable disease who achieve a CR or PR, DoR is defined as the time from the first documented CR or PR until the first documented disease progression according to RECIST v1.1 or death from any cause, whichever occurs first.

    Time frame: Up to 2 years

  6. Disease Control Rate (DCR) per RECIST v1.1

    Among participants with measurable disease, DCR is defined as the percentage of participants who achieve a CR, PR, or stable disease (SD) according to RECIST v1.1.

    Time frame: Up to 2 years

  7. Incidence, nature, and severity of AEs graded according to CTCAE v6.0 (Expansion phase)

    An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. All AE events will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 6.0.

    Time frame: Up to 2 years

  8. PK profile: peak plasma concentration (Cmax) of GI-102 when combined with pasritamig

    Plasma concentrations of GI-102 will be measured at specified time points following administration of GI-102 in combination with pasritamig to determine the maximum observed plasma concentration (Cmax).

    Time frame: Up to 2 years

  9. PK profile: half-life (T1/2) of GI-102 when combined with pasritamig

    Plasma concentrations of GI-102 will be measured at specified time points following administration of GI-102 in combination with pasritamig to determine the terminal half-life (T1/2) of GI-102.

    Time frame: Up to 2 years

  10. PK profile: area under the plasma concentration-time curve (AUC) of GI-102 when combined with pasritamig

    Plasma concentrations of GI-102 will be measured at specified time points following administration of GI-102 in combination with pasritamig to determine the area under the plasma concentration-time curve (AUC) of GI-102.

    Time frame: Up to 2 years

Other outcomes

  1. Immune cell phenotyping in peripheral blood

    Immune cell populations and their changes following study treatment will be assessed in peripheral blood using flow cytometry.

    Time frame: Up to 2 years

  2. Overall Response Rate (ORR) per iRECIST

    ORR is defined as the percentage of participants who achieve a partial response (PR) or complete response (CR) according to the iRECIST criteria.

    Time frame: Up to 2 years

  3. Overall Survival (OS)

    Overall survival (OS) is defined as the time from the first dose of study treatment to death from any cause.

    Time frame: Up to 2 years

  4. Incidence of anti-GI-102 antibody (ADA)

    Serum samples will be analyzed using a validated assay to determine the incidence of anti-GI-102 antibodies (ADA).

    Time frame: Up to 2 years

  5. Incidence of Neutralizing Antibody (Nab) Against GI-102

    Serum samples that are positive for anti-GI-102 antibodies (ADA) will be further analyzed using a validated assay to determine the incidence of neutralizing antibodies (Nab).

    Time frame: Up to 2 years

07

Study locations

5 of 6 sites recruiting
  • Columbia University Medical Center
    New York, New York 10032, United States
    Not yet recruiting
    • Mark N. Stein, M.D. · Principal investigator
  • The Catholic University of Korea Seoul ST.MARY'S Hospital
    Seoul, Banpo-daero 06591, South Korea
    Recruiting
    • In Ho Kim · Principal investigator
  • Korea University Anam Hospital
    Seoul, Seongbuk-gu 02841, South Korea
    Recruiting
    • Jwa Hoon Kim, M.D. · Principal investigator
  • Ewha Womans University Mokdong Hospital
    Seoul, Yangcheon-gu 07985, South Korea
    Recruiting
    • Jeong Min Cho · Principal investigator
  • Yonsei University Health System, Severance Hospital
    Seoul, 03722, South Korea
    Recruiting
    • Sang Joon Shin, M.D., Ph.D. · Principal investigator
  • Asan Medical Center
    Seoul, 05505, South Korea
    Recruiting
    • Jae Lyun Lee, M.D., Ph.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Mar 2029, 29 months later.

Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's planned 29 months is below that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2026
First posted
Oct 13, 2026
StartEst.
Oct 12, 2026
Primary completionEst.
Mar 31, 2029
CompletionEst.
Sep 30, 2029
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites changed recruiting status (4 now recruiting)
Show 4 sites
  • Ewha Womans University Mokdong Hospital · Seoul, South KoreaNot yet recruiting→Recruiting
  • The Catholic University of Korea Seoul ST.MARY'S Hospital · Seoul, South KoreaNot yet recruiting→Recruiting
  • Korea University Anam Hospital · Seoul, South KoreaNot yet recruiting→Recruiting
  • Asan Medical Center · Seoul, South KoreaNot yet recruiting→Recruiting
across 2 updates, Oct 19, 2026 – Nov 9, 2026
Interventions
Arm changed Safety run-in: GI-102 Q6W + pasritamig Q6W→Safety run-in: GI-102 + pasritamig (Schedule A); Safety run-in: GI-102 Q3W + pasritamig Q6W→Safety run-in: GI-102 + pasritamig (Schedule B)
across 2 updates, Oct 19, 2026 – Nov 9, 2026
Registered
First appeared on the registry
Oct 13, 2026
Show all 3 updates
  1. Nov 9, 2026
    3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • The Catholic University of Korea Seoul ST.MARY'S Hospital · Seoul, South KoreaNot yet recruiting→Recruiting
    • Korea University Anam Hospital · Seoul, South KoreaNot yet recruiting→Recruiting
    • Asan Medical Center · Seoul, South KoreaNot yet recruiting→Recruiting
    Interventions Arm changed Safety run-in: GI-102 Q6W + pasritamig→Safety run-in: GI-102 + pasritamig (Schedule A); Safety run-in: GI-102 Q3W + pasritamig→Safety run-in: GI-102 + pasritamig (Schedule B)
    + 1 other change: verification date
  2. Oct 19, 2026
    Ewha Womans University Mokdong Hospital is now Recruiting
    Interventions Arm changed Safety run-in: GI-102 Q6W + pasritamig Q6W→Safety run-in: GI-102 Q6W + pasritamig; Safety run-in: GI-102 Q3W + pasritamig Q6W→Safety run-in: GI-102 Q3W + pasritamig
  3. Oct 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07871435
Lead sponsor
GI Innovation, Inc.
Responsible party
Sponsor
First posted
Oct 13, 2026
Start date
Oct 12, 2026 (estimated)
Primary completion
Mar 31, 2029 (estimated)
Completion
Sep 30, 2029 (estimated)
Last update
Nov 9, 2026

Study contacts

Kwang-Soo Shin
Contact
Clinical-102-P201@gi-innovation.com
+82-2-404-2003

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102

Start the discussion